Ces3/TGH deficiency improves dyslipidemia and reduces atherosclerosis in Ldlr-/-mice

Circulation Research

Volumn 111, Issue 8, 2012, Pages 982-990

  Lian, Jihong ^a   Quiroga, Ariel D ^a   Li, Lena ^a   Lehner, Richard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

apolipoprotein B; atherosclerosis; carboxylesterase; cholesterol homeostasis; insulin resistance; lipase; lipoproteins

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE COURSE; DYSLIPIDEMIA; ENZYME DEFICIENCY; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HYPERTRIGLYCERIDEMIA; INSULIN SENSITIVITY; LIPID DIET; LIPOGENESIS; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL HYDROLASE DEFICIENCY;

ANIMALS; AORTA; APOLIPOPROTEINS B; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; CORONARY ARTERY DISEASE; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; FATTY ACIDS; FATTY LIVER; FEMALE; INSULIN; INSULIN RESISTANCE; LIPASE; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; RECEPTORS, LDL;

EID: 84866981413     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.112.267468     Document Type: Article

References (46)

1. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104:503-516. (Pubitemid 32201946)
2. Young SG, Parthasarathy S. Why are low-density lipoproteins atherogenic? West J Med. 1994;160:153-164. (Pubitemid 24071160)
3. Wiggins D, Gibbons GF. The lipolysis/esterification cycle of hepatic triacylglycerol: its role in the secretion of very-low-density lipoprotein and its response to hormones and sulphonylureas. Biochem J. 1992;284:457-462.
4. Yang LY, Kuksis A, Myher JJ, Steiner G. Origin of triacylglycerol moiety of plasma very low density lipoproteins in the rat: structural studies. J Lipid Res. 1995;36:125-136.
5. Yang LY, Kuksis A, Myher JJ, Steiner G. Contribution of de novo fatty acid synthesis to very low density lipoprotein triacylglycerols: evidence from mass isotopomer distribution analysis of fatty acids synthesized from 2H6ethanol. J Lipid Res. 1996;37:262-274.
6. Lankester DL, Brown AM, Zammit VA. Use of cytosolic triacylglycerol hydrolysis products and of exogenous fatty acid for the synthesis of triacylglycerol secreted by cultured rat hepatocytes. J Lipid Res. 1998;39:1889-1895. (Pubitemid 28411177)
7. Lehner R, Vance DE. Cloning and expression of a cDNA encoding a hepatic microsomal lipase that mobilizes stored triacylglycerol. Biochem J. 1999;343:1-10. (Pubitemid 29473871)
8. Gilham D, Ho S, Rasouli M, Martres P, Vance DE, Lehner R. Inhibitors of hepatic microsomal triacylglycerol hydrolase decrease very low density lipoprotein secretion. FASEB J. 2003;17:1685-1687.
9. Gilham D, Alam M, Gao W, Vance DE, Lehner R. Triacylglycerol hydrolase is localized to the endoplasmic reticulum by an unusual retrieval sequence where it participates in VLDL assembly without utilizing VLDL lipids as substrates. Mol Biol Cell. 2005;16:984-996. (Pubitemid 40165587)
10. Dolinsky VW, Sipione S, Lehner R, Vance DE. The cloning and expression of a murine triacylglycerol hydrolase cDNA and the structure of its corresponding gene. Biochim Biophys Acta. 2001;1532:162-172. (Pubitemid 32706436)
11. Wang H, Gilham D, Lehner R. Proteomic and lipid characterization of apolipoprotein B-free luminal lipid droplets from mouse liver microsomes: implications for very low density lipoprotein assembly. J Biol Chem. 2007;282:33218-33226. (Pubitemid 350159294)
12. Wei E, Alam M, Sun F, Agellon LB, Vance DE, Lehner R. Apolipoprotein B and triacylglycerol secretion in human triacylglycerol hydrolase transgenic mice. J Lipid Res. 2007;48:2597-2606. (Pubitemid 350272844)
13. Wei E, Ben Ali Y, Lyon J, Wang H, Nelson R, Dolinsky VW, Dyck JR, Mitchell G, Korbutt GS, Lehner R. Loss of TGH/Ces3 in mice decreases blood lipids, improves glucose tolerance, and increases energy expenditure. Cell Metab. 2010;11:183-193.
14. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993;92:883-893. (Pubitemid 23262411)
15. Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res. 1995;36:2320-2328.
16. Getz GS, Reardon CA. Diet and murine atherosclerosis. Arterioscler Tromb Vasc Biol. 2006;26:242-249. (Pubitemid 43732181)
17. Trigatti B, Rayburn H, Vinals M, Braun A, Miettinen H, Penman M, Hertz M, Schrenzel M, Amigo L, Rigotti A, Krieger M. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci USA. 1999;96:9322-9327. (Pubitemid 29374753)
18. Lhotak S, Zhou J, Austin RC. Immunohistochemical detection of the unfolded protein response in atherosclerotic plaques. Methods Enzymol. 2011;489:23-46.
19. Elovson J, Chatterton JE, Bell GT, Schumaker VN, Reuben MA, Puppione DL, Reeve JR Jr, Young NL. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res. 1988;29:1461-1473. (Pubitemid 19013040)
20. Schumaker VN, Phillips ML, Chatterton JE. Apolipoprotein B and low-density lipoprotein structure: implications for biosynthesis of triglyceride-rich lipoproteins. Adv Protein Chem. 1994;45:205-248.
21. Lian J, Wei E, Wang SP, Quiroga AD, Li L, Pardo AD, van der Veen J, Sipione S, Mitchell GA, Lehner R. Liver specific inactivation of carboxylesterase 3/triacylglycerol hydrolase decreases blood lipids without causing severe steatosis. Hepatology. 2012.
22. Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Phys. 2003;111: 241-248.
23. Bergman Richard N. AM. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab. 2000;11:351-356.
24. Fisher EA, Ginsberg HN. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem. 2002;277:17377-17380. (Pubitemid 34967535)
25. Fisher EA, Zhou M, Mitchell DM, Wu X, Omura S, Wang H, Goldberg AL, Ginsberg HN. The degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70. J Biol Chem. 1997;272:20427-20434. (Pubitemid 27355595)
26. Nicholls SJ, Rye KA, Barter PJ. High-density lipoproteins as therapeutic targets. Curr Opin Lipidol. 2005;16:345-349. (Pubitemid 40839765)
27. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. 2006;116:3090-3100. (Pubitemid 44878620)
28. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;1:16-19.
29. Farmer JA, Liao J. Evolving concepts of the role of high-density lipoprotein in protection from atherosclerosis. Curr Atheroscler Rep. 2011;13:107-114.
30. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2001;21:13-27. (Pubitemid 32061923)
31. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. 2000;41: 1495-1508.
32. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21: 481-488. (Pubitemid 32323377)
33. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95: 764-772. (Pubitemid 39390578)
34. Chandler CE, Wilder DE, Pettini JL, Savoy YE, Petras SF, Chang G, Vincent J, Harwood HJ Jr. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res. 2003;44:1887-1901. (Pubitemid 37356661)
35. Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148-156. (Pubitemid 46089675)
36. Raabe M, Veniant MM, Sullivan MA, Zlot CH, Bjorkegren J, Nielsen LB, Wong JS, Hamilton RL, Young SG. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J Clin Invest. 1999;103:1287-1298. (Pubitemid 29218299)
37. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46:1081-1090. (Pubitemid 350144772)
38. Caballero F, Fernandez A, De Lacy AM, Fernandez-Checa JC, Caballeria J, Garcia-Ruiz C. Enhanced free cholesterol, SREBP-2 and STAR expression in human NASH. J Hepatol. 2009;50:789-796.
39. Mari M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, Fernandez-Checa JC, Garcia-Ruiz C. Mitochondrial free cholesterol loading sensitizes to Tnf-and Fas-mediated steatohepatitis. Cell Metab. 2006;4:185-198. (Pubitemid 44307975)
40. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabet Care. 1991;14:173-194.
41. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607. (Pubitemid 19004941)
42. Knudsen P, Eriksson J, Lahdenpera S, Kahri J, Groop L, Taskinen MR. Changes of lipolytic enzymes cluster with insulin resistance syndrome: Botnia study group. Diabetologia. 1995;38:344-350.
43. Baynes C, Henderson AD, Anyaoku V, Richmond W, Hughes CL, Johnston DG, Elkeles RS. The role of insulin insensitivity and hepatic lipase in the dyslipidaemia of type 2 diabetes. Diabet Med. 1991;8: 560-566.
44. Dorn C, Riener MO, Kirovski G, Saugspier M, Steib K, Weiss TS, Gäbele E, Kristiansen G, Hartmann A, Hellerbrand C. Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int J Clin Exp Pathol. 2010;3: 505-514.
45. Harmancey R, Wilson CR, Wright NR, Taegtmeyer H. Western diet changes cardiac acyl-CoA composition in obese rats: a potential role for hepatic lipogenesis. J Lipid Res. 2010;51:1380-1393.
46. Wong RH, Sul SH. Insulin signaling in fatty acid and fat synthesis: a transcriptional perspective. Curr Opin Pharmacol. 2010;10:684-691.